Streetbeat News

Products Services

DBVT

DBV Technologies has announced positive interim results from its ongoing Phase 3 Open-Label Extension to the EPITOPE Trial of Viaskin Peanut in toddlers. The treatment showed improvement across all efficacy parameters between months 12 and 24. Notably, 81.3% of subjects reached an eliciting dose of ≥1,000 mg after 24 months of treatment. There were no treatment-related anaphylactic or serious treatment-related adverse events in the second year of active treatment. The company will present these results at the American College of Allergy, Asthma, and Immunology annual meeting.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 11:46 pm

OUST

Ouster, Inc. (NYSE:OUST), a provider of lidar sensors, announced major software achievements to serve the growing demand for lidar-powered smart infrastructure solutions. This includes the unification of Blue City and Ouster Gemini, the addition of new AI perception models, and booking software coupled sales worth millions of dollars. Ouster expanded its product portfolio to include software solutions earlier this year, starting with the release of Ouster Gemini, its digital lidar perception platform. The company then added Blue City, a traffic management solution, to its offerings following its merger with Velodyne. Ouster booked software coupled sales worth millions of dollars in the third quarter, including a significant deal to deploy its digital lidar hardware coupled with Ouster Gemini at over 130 logistics sites.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:44 pm

NTBL

Notable Labs (NASDAQ:NTBL) has published data from an ex vivo study demonstrating the potential of its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML). The study found that tretinoin, a standard-of-care agent in acute promyelocytic leukemia (APL), enhanced the ex vivo effects of FLA and AZA, suggesting a potential rationale for use of CD38-targeting agents to further enhance the envisioned treatment effect.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:41 pm

QGEN

QIAGEN (NYSE:QGEN) has announced the launch of three new kits for use on its QIAcuity systems and a major new software update. The new kits and software are designed to expand the use of digital PCR technology in areas such as cell and gene therapies, DNA and RNA quantification, and food and pharmaceutical safety. The company also plans to launch the QIAcuity Software 2.5 update in November, which will help researchers determine two key features of digital PCR analyses.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:31 pm

SANA

Sana Biotechnology, Inc. (NASDAQ:SANA) has received FDA clearance for its Investigational New Drug (IND) application to initiate a study of SC291, a hypoimmune-modified, CD19-directed allogeneic CAR T therapy, for patients with multiple B-cell mediated autoimmune diseases. The company plans to begin treating patients soon and expects to disclose initial safety and efficacy data in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:28 pm

XGN

Exagen Inc. (NASDAQ:XGN) and Johns Hopkins University have announced an exclusive license agreement for the development of novel patented biomarkers for therapeutic management of patients with lupus nephritis. Exagen will acquire a worldwide exclusive license to an invention from the laboratory of Michelle Petri, MD, MPH, and Andrea Fava, MD. The company plans to develop these biomarkers into assays to aid diagnostic and treatment decisions.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:26 pm

LYEL

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has received FDA Orphan Drug Designation for LYL845, a product candidate for the treatment of stage IIB-IV melanoma. The designation provides certain incentives, including tax credits for qualified clinical trials and potential seven-year marketing exclusivity upon FDA approval. LYL845 is currently being investigated in a Phase 1 clinical trial in patients with advanced melanoma, non-small cell lung cancer, and colorectal cancer. Initial data from the trial are expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:22 pm

U

Unity Software has announced plans to implement a restructuring strategy within this quarter, which is expected to be completed by the end of Q1 2024. The plan may include discontinuing certain product offerings, reducing the workforce, and downsizing the office footprint.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:21 pm

AAPL

Taylor Swift has been named Apple Music's Artist of the Year, with 65 of her songs dominating Apple Music's Global Daily Top 100 in the first 10 months of the year. Apple Inc's Vice President of Apple Music and Beats, Oliver Schusser, acknowledged Swift's impact on the music industry. Apple Music is now showcasing Swift's musical journey, with her album 'Midnights' being the largest debut by a female artist in Apple Music history.

Portfolio Pulse from Franca Quarneti

November 09, 2023 | 10:15 pm

ENSC

Ensysce Biosciences Inc. is expected to release the clinical study results of PF614-201 by the end of the year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:07 pm